Researchers have reached significant milestones in a clinical program for prostate cancer treatment called WATER IV, focusing on a new therapy known as Aquablation®. They have completed enrollment for a study comparing Aquablation therapy to the standard surgical treatment, radical prostatectomy, with 280 participants. Additionally, they received FDA approval for a second study that will evaluate Aquablation against active surveillance in men with lower-risk prostate cancer. This second study aims to determine if Aquablation can provide a better quality-of-life-preserving treatment option for those who might otherwise wait for their condition to worsen.

This research is particularly relevant for men facing prostate cancer, as it could offer a new, less invasive treatment option that may help maintain quality of life. The studies will track outcomes over ten years, assessing not only how well the treatments control the disease but also their effects on urinary, sexual, and overall function. If successful, Aquablation could become a preferred option for men who want to avoid the potential side effects of more aggressive treatments.

Currently, the WATER IV studies are in the early stages, with the first study fully enrolled and results expected by spring 2027. The second study is set to enroll up to 333 participants globally. While the potential benefits of Aquablation are promising, it is important to note that these findings are not yet proven in large-scale human trials, and more research is needed to fully understand its effectiveness compared to existing treatments.

Source: globenewswire.com